{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"}],"title":"ECOG score 0"},{"measurements":[{"groupId":"OG000","value":"78"}],"title":"ECOG score 1"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"ECOG score 2"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"ECOG score 3"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"ECOG score 4"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"ECOG score 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"}],"title":"ECOG score 0"},{"measurements":[{"groupId":"OG000","value":"50"}],"title":"ECOG score 1"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"ECOG score 2"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"ECOG score 3"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"ECOG score 4"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"ECOG score 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"}],"units":"Participants"}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"description":"ECOG (Eastern Cooperative Oncology Group) Performance Status is scored on a 6-point scale where higher scores indicate a worse outcome. ECOG scores include the following:\n\n* 0 = fully active, able to carry on all pre-disease performance without restriction\n* 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\n* 2 = ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours\n* 3 = capable of only limited self-care; confined to bed or chair more than 50% of waking hours\n* 4 = completely disabled; cannot carry on any self-care; totally confined to bed or chair\n* 5 = dead","groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-treated population - all participants who received at least 1 dose of treatment. Results are presented for participants with data available for analysis at end of treatment.","reportingStatus":"POSTED","timeFrame":"Baseline and end of treatment (up to 599 days)","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline and End of Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}